Since 1984 we have autografted a total of 60 patients with AML in second complete remission (CR) utilizing the BAVC (BCNU, amsacrine, vepesid, cytosine-arabinoside) conditioning regimen and unpurged marrow. Projected disease-free survival (DFS) probability is 42% at 10 years. Autografting was performed at a median interval of 2 months (range 1-13) from second CR, The median duration of first CR was 14 months (range 1-43) and lasted less than or equal to 12 months in 27/60 patients, Three early deaths (5%) occurred, 30 patients relapsed after a median of 6 months from transplant (range 2-28) and, of the remaining 27 patients, 26 are in continuous CR (CCR) after a median follow up of 60 months (range 6-122), while the last patient committed suicide 7 years after ABMT when she was still in CCR. A first CR duration >12 months is correlated with a significantly better overall survival probability (61 vs 25%, P = 0.02), while no factors influence DFS. Outcome of patients who relapsed after autografting has been analyzed separately; a longer overall survival after relapse is correlated with a longer duration of the second CR (62% at 34 months for patients who relapsed after >12 months from the autograft vs 5% for the others, P=0.001). These results confirm that AML patients autografted in second CR with BAVC regimen and unpurged marrow have the possibility of becoming long-term DFS and can therefore be cured.

BAVC regimen and autograft for acute myelogenous leukemia in second complete remission / Meloni, Giovanna; Vignetti, Marco; G., Avvisati; S., Capria; Micozzi, Alessandra; Giona, Fiorina; Mandelli, Franco. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - STAMPA. - 18:4(1996), pp. 693-698.

BAVC regimen and autograft for acute myelogenous leukemia in second complete remission

MELONI, Giovanna;VIGNETTI, Marco;MICOZZI, Alessandra;GIONA, Fiorina;MANDELLI, Franco
1996

Abstract

Since 1984 we have autografted a total of 60 patients with AML in second complete remission (CR) utilizing the BAVC (BCNU, amsacrine, vepesid, cytosine-arabinoside) conditioning regimen and unpurged marrow. Projected disease-free survival (DFS) probability is 42% at 10 years. Autografting was performed at a median interval of 2 months (range 1-13) from second CR, The median duration of first CR was 14 months (range 1-43) and lasted less than or equal to 12 months in 27/60 patients, Three early deaths (5%) occurred, 30 patients relapsed after a median of 6 months from transplant (range 2-28) and, of the remaining 27 patients, 26 are in continuous CR (CCR) after a median follow up of 60 months (range 6-122), while the last patient committed suicide 7 years after ABMT when she was still in CCR. A first CR duration >12 months is correlated with a significantly better overall survival probability (61 vs 25%, P = 0.02), while no factors influence DFS. Outcome of patients who relapsed after autografting has been analyzed separately; a longer overall survival after relapse is correlated with a longer duration of the second CR (62% at 34 months for patients who relapsed after >12 months from the autograft vs 5% for the others, P=0.001). These results confirm that AML patients autografted in second CR with BAVC regimen and unpurged marrow have the possibility of becoming long-term DFS and can therefore be cured.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/415185
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 32
social impact